Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
Portfolio Pulse from
Celldex Therapeutics has initiated a Phase 1 study for CDX-622, a bispecific antibody aimed at treating inflammatory diseases. The study involves healthy volunteers and targets pathways involved in chronic inflammation.
November 20, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celldex Therapeutics has dosed the first patient in a Phase 1 study of CDX-622, a bispecific antibody for inflammatory diseases. This marks a significant step in their drug development pipeline.
The initiation of a Phase 1 study is a positive development for Celldex, indicating progress in their drug development pipeline. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100